This formula is designed around four distinct biological targets that each contribute independently to under-eye aging and appearance concerns:

Dual anti-puffiness coverage: Caffeine targets the vascular component of puffiness — vasoconstriction and reduced fluid extravasation from capillaries. Triamcinolone targets the inflammatory component — suppressing cytokines, reducing vascular permeability, and interrupting allergic and reactive edema cascades. Most patients experience both vascular and inflammatory contributions to periorbital puffiness; addressing only one mechanism leaves meaningful unmet clinical need.

Dual collagen stimulation: Tretinoin stimulates new collagen via RAR-mediated gene transcription in the dermis. Glycolic acid stimulates fibroblast collagen production via a distinct pathway at the dermal-epidermal junction. Two independent collagen signals in a zone where collagen loss is among the most visible signs of periorbital aging.

Surface and structural renewal: Glycolic acid resurfaces the epidermis, clearing dull, pigmented, dead surface cells. Tretinoin rebuilds the epidermis from below with accelerated generation of healthy, structurally sound keratinocytes and simultaneously drives dermal remodeling. Surface cleared and structure rebuilt simultaneously.

Triple pigmentation correction: Tretinoin normalizes aberrant melanocyte activity. Glycolic acid accelerates the exfoliation of melanin-loaded surface cells. Caffeine improves periorbital microcirculation, reducing the vascular (hemoglobin-related) component of dark circles. Three mechanisms targeting the three primary contributors — epidermal melanin, surface cell accumulation, and underlying vascularity — in one formula.

Built-in tolerability infrastructure: Triamcinolone suppresses the inflammatory reaction that makes retinoid and AHA therapy poorly tolerated in many patients when applied near sensitive periorbital skin. Rather than requiring patients to choose between clinical potency and tolerability, the formula incorporates its own anti-inflammatory buffer — allowing the retinoid and acid chemistry to work at effective concentrations without the irritation, stinging, and reactive swelling that would otherwise limit periorbital use.

With consistent twice-daily use as part of a supervised skincare protocol, Puffy Eye Cream supports:

Visible reduction in under-eye puffiness and swelling — both vascular (caffeine) and inflammatory (triamcinolone) origin

Reduced appearance of under-eye bags with consistent daily use

Improvement in dark circles through microcirculatory enhancement, epidermal melanin reduction, and surface cell turnover

Smoothing of fine lines and crepiness in the periorbital zone through dual-pathway collagen stimulation

Improved structural firmness and skin quality in the under-eye area over time

Resurfaced, more even-textured periorbital skin through combined retinoid and AHA exfoliation

Brightened, more luminous skin appearance as dull, pigmented surface cells are cleared

Reduced periorbital redness and reactivity via corticosteroid anti-inflammatory activity

Antioxidant protection against UV-driven free radical damage in the delicate periorbital zone

Improvement in overall periorbital skin quality, tone, and appearance with continued use

Results vary by individual. Puffiness and redness reduction is often noticeable within days to weeks of consistent use. Meaningful improvement in fine lines, dark circles, and skin texture typically develops over 6–12 weeks. Structural collagen remodeling continues to improve through 3–6 months of sustained use.

Apply to the under-eye area 1–2 times daily. This formula is designed for periorbital application — specifically the under-eye zone below the orbital bone. Do not apply directly to the eyelid, and avoid contact with the eyes themselves.

Application Instructions:

Cleanse the face and pat dry. The under-eye area does not need to be fully dry before application — unlike tretinoin on other areas of the face, the buffering effect of the other actives makes the periorbital skin less sensitive to application timing in most patients.

Dispense a very small amount — a fraction of a pea-sized quantity is sufficient for the under-eye area of both eyes. This skin is thin and absorbs efficiently; over-application does not improve outcomes and increases irritation risk.

Apply gently using the ring finger — the weakest finger, applying the least mechanical pressure — by lightly patting (not rubbing) the cream into the under-eye area. Avoid dragging or pulling the delicate periorbital skin.

Apply from the inner corner outward, following the natural curve of the orbital bone.

Do not apply closer to the eye than the orbital bone margin.

Allow to absorb before applying any other eye area products.

Morning Use: If applying in the morning, follow immediately with a broad-spectrum SPF 30 or higher sunscreen. Tretinoin increases photosensitivity — morning application without sun protection is not recommended.

Twice-Daily Use: Evening application benefits from the skin's overnight repair activity and avoids the immediate sun exposure concern. Patients who choose once-daily use should prefer evening application.

Starting Protocol: Patients new to retinoid or AHA periorbital therapy may wish to begin with once-daily evening application for the first 1–2 weeks, advancing to twice-daily as tolerated. The triamcinolone component significantly reduces the adjustment irritation typical of periorbital retinoid introduction, but individual sensitivity varies.

Puffy Eye Cream is a prescription-only compounded medication containing a topical corticosteroid and a teratogenic retinoid. Patients must be fully counseled before initiating therapy.

Contraindications:

Pregnancy: Tretinoin is teratogenic. While systemic absorption from topical periorbital application at therapeutic concentrations is very low, it is not zero. Puffy Eye Cream is contraindicated during pregnancy. Women of reproductive age must use reliable contraception during treatment and discontinue immediately if pregnancy occurs or is planned.

Breastfeeding: Safety of topical tretinoin during lactation has not been established. Use is not recommended.

Glaucoma or elevated intraocular pressure: Topical corticosteroids applied near the eye carry a documented risk of elevated intraocular pressure (IOP) with prolonged use, and can rarely precipitate or worsen glaucoma in predisposed individuals. Patients with a personal or family history of glaucoma, ocular hypertension, or any diagnosed optic nerve pathology must discuss use with their prescribing provider and ophthalmologist before initiating therapy. This product should not be applied to the eyelid or directly over the eye.

Active periorbital infection: Do not apply to periorbital skin affected by active bacterial, viral (including herpes simplex / cold sores), or fungal infection. Corticosteroids can mask infection signs and suppress local immune response.

Rosacea of the periorbital area: Corticosteroid use on rosacea-affected skin requires individualized provider evaluation; prolonged use may worsen rosacea.

Known retinoid sensitivity: Patients with documented allergy or intolerance to tretinoin or other retinoids should not use this product.

Potential Side Effects:

Tretinoin- and glycolic acid-related:

Mild stinging, tingling, or warmth on initial application — most common in patients new to periorbital retinoid or AHA use; typically resolves with continued use

Mild redness or peeling during the adjustment period

Increased periorbital photosensitivity — managed by mandatory daily SPF when used in the morning

Triamcinolone-related:

With prolonged continuous use: potential for skin atrophy, telangiectasia, or perioral (in this context, periorbital) dermatitis — risks managed by using the lowest effective dose for the shortest necessary duration, as prescribed

Periorbital corticosteroid use can elevate intraocular pressure — patients should report any changes in vision, eye pressure, or discomfort to their provider and eye care specialist

Caffeine-related:

Exceptionally well tolerated topically; rare contact sensitivity in caffeine-allergic patients

General:

Contact dermatitis in patients with allergy to any formula component

Eye irritation if product migrates into the eye — rinse thoroughly with water if this occurs

Do not apply to:

Eyelids

Directly over the eye

Broken, infected, or acutely inflamed skin

Areas beyond the periorbital under-eye zone without provider direction

Other topical retinoids: Concurrent use of additional retinoid products (retinol, retinaldehyde, adapalene) in the periorbital area significantly increases irritation risk without proportional benefit. Discuss concurrent use with your provider.

Other topical exfoliating acids: Additional AHAs (lactic acid, mandelic acid) or BHAs (salicylic acid) applied concurrently to the periorbital area increase barrier disruption risk. Avoid combining without provider direction.

Immunosuppressants: Patients on systemic immunosuppressive therapy should ensure all prescribing providers are aware of the topical corticosteroid component of this formula.

Topical immunomodulators (tacrolimus, pimecrolimus): May interact with corticosteroid activity in the periorbital zone; discuss concurrent use with your provider.

Photosensitizing medications: Certain antibiotics, diuretics, and antifungals increase photosensitivity additively with tretinoin. Daily SPF is essential when using any photosensitizing agent alongside this formula.

Store at room temperature, 68°F – 77°F (20°C – 25°C), away from direct heat, humidity, and light

Keep container tightly closed

Tretinoin is light-sensitive — store in original packaging away from direct sunlight

Do not freeze

Keep out of reach of children

Do not use beyond the labeled expiration date